

AstraZeneca Call for Grant Applications (Radio Conjugates 081426)

Submission / Review Timeline:	Accepting applications until 9 AM EST on 09/20/2024 internal review will be ongoing during this time period
Primary Area of Focus	Oncology – Prostate Cancer
Therapeutic Area	PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Educational Format	Live, Virtual Live with Audio and/or Video plus Enduring Component; Certified Education Credit for the Target Audience; Format to include, but not limited to, visual and kinesthetic learning styles. Examples: podcasts, panel discussions, simulations, patient case studies, interactive, digital or video-based learning.
Educational Audience:	Medical oncologists, Urologists, Radiation Oncologists, Nuclear Medics, Advanced Practice Providers, and Pathologists, primarily with Molecular Pathology specialties
Estimated Program Start Date:	October 2026 – January 2027
Program Cost:	≤\$300,000
Request Code	<u>Radio Conjugates 081426</u>
Website URL	MEGO website: www.astrazenecagrants.com Grant Application: https://www.cybergrants.com/astrazeneca/full

The Request:

We welcome submissions for independent medical education grants (IME/CME) from educational providers who believe they can meet the high demands of a time-sensitive rapid grant submission and deployment of virtual medical education. Submitted applications should include a formal letter of request and grant proposal with needs assessment, learning objectives, agenda, and budget schedule.

AstraZeneca, Medical Education Grants Office (MEGO):

AstraZeneca is committed to supporting quality independent medical education that meets an educational need by providing information to healthcare professionals to improve patient care and outcomes. We support education that furthers the understanding of emerging therapies based on a documented unmet need and supports the efforts of health care professionals to broaden patient knowledge and awareness of disease states and treatment options. Our grant support is focused on areas of high unmet need that overlap with our medical areas of interest. For more information, please visit www.astrazenecagrants.com

Background on Educational Needs in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Despite advances in the management of metastatic castration-resistant prostate cancer (mCRPC), important educational needs remain as treatment strategies become increasingly complex. Clinicians must navigate evolving treatment sequencing, the expanding role of PSMA-targeted radioligand therapies, and the growing use of molecular and imaging biomarkers to guide care. Emerging radiopharmaceutical approaches have increased the need for education on the differences between alpha- and beta-emitting therapies, including their radiobiology, safety considerations, and potential roles in clinical practice.

Additional education is needed on appropriate patient identification, interpretation and application of PSMA-targeted imaging, selection of patients for available and emerging radioligand therapies, and management of patients with advanced disease following multiple lines of treatment. Clinicians also require greater understanding of multidisciplinary care models, treatment logistics, toxicity management, patient counseling, and practical factors that influence treatment access and delivery. Gaps exist in understanding how differences among radiopharmaceutical classes may influence patient selection, monitoring, and interpretation of clinical evidence.

These gaps highlight the need to improve clinician knowledge of biomarker-informed treatment decisions, PSMA-targeted imaging, radioligand therapy integration, treatment sequencing, and multidisciplinary care strategies to optimize outcomes for patients with advanced mCRPC.

Program Requirements:

The Program must be accredited and fully compliant with the criteria and/or standards of commercial support for ACCME, AAFP, AOA, ACPE, ANCC, AANP, NCCPA, CAP, AMP, USCAP. Furthermore, the program will be educational and non-promotional in nature and will be planned, designed and implemented in accordance with the U.S. Food and Drug Administration's Guidance on Industry-Supported Scientific and Educational Activities ("Policy Statement").

The Policy Statement and the ACCME Standards require, among other things, that (i) Institute conduct the Program independently and without control or influence by AstraZeneca over the Program's planning, content (including the selection of speakers or moderators), or execution; (ii) the Program be free of commercial bias for or against any product; (iii) Institution make meaningful disclosure of AstraZeneca support of the Program and any prior relationship between Institution and AstraZeneca, and the relationship, if any, between AstraZeneca and the speakers selected by Institution; and (iv) AstraZeneca not engage in, and Institution not permit any other sponsor to engage in, promotional activities in or near the Program room or advertise its products in any materials disseminated as part of the Program.

In addition, Institution is required by the Policy Statement and the ACCME Standards to ensure that any product discussions at the Program be accurate, objective, balanced and scientifically rigorous. This includes a balanced discussion of each product and of treatment alternatives, that limitations on data be disclosed, that unapproved uses be identified as such, and that for live presentations there be opportunities for questioning or debate.